Liisa Bayko
Stock Analyst at Evercore ISI Group
(4.35)
# 413
Out of 4,734 analysts
81
Total ratings
51.52%
Success rate
18.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $10 → $12 | $7.45 | +61.07% | 5 | Jan 13, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $1.22 | +309.84% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.44 | +58.84% | 2 | Dec 11, 2024 | |
| SVRA Savara | Downgrades: In-Line | $7 → $5 | $2.93 | +70.65% | 3 | Nov 13, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $18.54 | +88.78% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $293.64 | +22.60% | 9 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $246.27 | +5.58% | 1 | Jun 25, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: In-Line | $27 → $2 | $2.58 | -22.48% | 2 | Jun 18, 2024 | |
| ANTX AN2 Therapeutics | Maintains: In-Line | $7 → $2 | $1.27 | +57.48% | 3 | May 16, 2024 | |
| ETNB 89bio | Maintains: Outperform | $37 → $33 | $6.31 | +422.98% | 4 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $38 | $25.14 | +51.15% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $438 | $422.00 | +3.79% | 17 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $14 | $18.37 | -23.79% | 4 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $40.00 | +100.00% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $7.50 | +140.00% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $6.86 | +264.43% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $5.25 | +1,080.95% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $66 → $60 | $40.53 | +48.04% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $7.77 | +350.45% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $33.37 | -28.08% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $8.58 | +249.65% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.20 | +212.50% | 1 | Feb 5, 2020 |
BioCryst Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $10 → $12
Current: $7.45
Upside: +61.07%
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $1.22
Upside: +309.84%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.44
Upside: +58.84%
Savara
Nov 13, 2024
Downgrades: In-Line
Price Target: $7 → $5
Current: $2.93
Upside: +70.65%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $18.54
Upside: +88.78%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $293.64
Upside: +22.60%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $246.27
Upside: +5.58%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: In-Line
Price Target: $27 → $2
Current: $2.58
Upside: -22.48%
AN2 Therapeutics
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.27
Upside: +57.48%
89bio
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $6.31
Upside: +422.98%
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $25.14
Upside: +51.15%
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $422.00
Upside: +3.79%
Sep 22, 2023
Maintains: Outperform
Price Target: $30 → $14
Current: $18.37
Upside: -23.79%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $40.00
Upside: +100.00%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $7.50
Upside: +140.00%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $6.86
Upside: +264.43%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $5.25
Upside: +1,080.95%
Jun 23, 2022
Downgrades: In-Line
Price Target: $66 → $60
Current: $40.53
Upside: +48.04%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $7.77
Upside: +350.45%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $33.37
Upside: -28.08%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $8.58
Upside: +249.65%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.20
Upside: +212.50%